CORRECT: Oxford BioDynamics plunges as annual loss widens; revenue up
17th Jan 2024 10:50
(Correcting headline to show loss widened, revenue rose) Read More
(Correcting headline to show loss widened, revenue rose) Read More
(Correcting headline to show profit and revenue rose) Read More
(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million. Read More
(Alliance News) - Oxford BioDynamics PLC shares surged on Wednesday as it announced a strategic deal with Bupa UK Insurance to enhance access to a "first-of-its-kind" blood test for cancer patients. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday said it has been issued an insurance reimbursement code for its EpiSwitch product from the American Medical Association. Read More
(Alliance News) - Shares in Oxford BioDynamics PLC leapt on Tuesday after it announced the validation of its EpiSwitch prostate screening test in its US clinical laboratory was now complete, ahead of schedule. Read More
(Alliance News) - Oxford BioDynamics PLC on Friday said it raised GBP543,577 after completing its PrimaryBid offer announced on Tuesday. Read More
Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovering and developing epigenetic biomarkers - Raises GBP5.6 million via accelerated bookbuild process and through direct subscription. 48.1 million shares are issued pursuant to the placing at an issue price of 11.0 pence per share. Subscribers have conditionally subscribed for 2.5 million shares at issue price. The placing shares and subscription shares represents around 25% of the company's issued share capital. Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the placing. Oxford BioDynamics have applied for shares to be admitted to trading on AIM, and expect this trading to commence on August 21. Read More
(Alliance News) - Oxford BioDynamics PLC on Tuesday said it plans to raise GBP7 million via a placing, subscription and retail offer of new shares in the company. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Oxford BioDynamics PLC said on Tuesday that the company will need to generate increased revenue or find additional funding in the remainder of the year, as its half-year loss widened. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers - Plans acceleration of final development and launch of PSE clinical test in both the UK and US, for availability in the fourth quarter. Commences certification of clinical testing facility within existing Oxford base. Reports the EpiSwitch CiRT blood test continues to gain traction in the US, posting record monthly orders in November and December 2022, and January and March 2023. Adds uptake of the test is growing, through both new and repeat orders. Intends to present both tests in a key note address at the 13th World Clinical Biomarker & Companion Diagnostics Europe Summit. Read More